← Leaderboards
Steven Idell
University Of Texas Hlth Ctr At Tyler
$6,820,677
Attributed
$13,921,805
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$21,658,014 · 10
By mechanism
R01$10,120,195 · 4
P01$9,714,402 · 3
R33$881,243 · 1
P50$868,103 · 1
U01$74,071 · 1
Top collaborators
- Andrey Komissarov14 shared
- Galina Florova12 shared
- Perenlei Enkhbaatar4 shared
- Mitsuo Ikebe4 shared
- Torry Alle Tucker4 shared
- Robert O. Williams4 shared
- Marla R Wolfson4 shared
- Henry Masur1 shared
Most similar at University Of Texas Hlth Ctr At Tyler
Same institution · by research overlap
- Andrey Komissarov$3,479,251
- Galina Florova$1,545,576
- Torry Alle Tucker$3,028,800
- Guoqing Qian$1,204,269
- Christian J Woods$24,690
Others in their field
Top investigators on “Fibrin”
- Robert T Tranquillo · University Of Minnesota Twin Cities$16,524,965
- Steven Kyle Grinspoon · Massachusetts General Hospital$15,631,556
- Pamela Susan Douglas · Duke University$15,631,556
- Bruce Furie · Beth Israel Deaconess Medical Center$15,095,734
- Guy L Reed · Harvard University (Sch Of Public Hlth)$12,951,913
- Peter D Caravan · Massachusetts General Hospital$12,495,120
Research focus
FibrinLungFibrinolysisPleuralInjuryPathogenesisPlasminogen Activator Inhibitor 1Morbidity - Disease RateUrokinaseLiquid SubstanceDoseEmpyemaThrombolytic TherapyPlasminMolecularOryctolagus CuniculusImproved OutcomeBiochemicalAffectBaseInnovationDepositionAcuteIncidence
Grant awards (43)
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$524,404
R01 · FY2024 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$535,106
R01 · FY2023 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$535,336
R01 · FY2022 · HL
Myocardin in the pathogenesis of pleural remodeling$475,566
R01 · FY2022 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$547,086
R01 · FY2021 · HL
Myocardin in the pathogenesis of pleural remodeling$475,566
R01 · FY2021 · HL
Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions$440,243
R33 · FY2021 · HL · contact PI
Myocardin in the pathogenesis of pleural remodeling$475,566
R01 · FY2020 · HL
Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions$441,000
R33 · FY2020 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$352,311
R01 · FY2020 · HL
Myocardin in the pathogenesis of pleural remodeling$474,488
R01 · FY2019 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$416,339
R01 · FY2019 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$448,525
R01 · FY2018 · HL
Airway Delivery of Fibrinolytic Therapy for ISALI$740,767
R01 · FY2017 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$364,557
R01 · FY2017 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$15,911
R01 · FY2017 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$15,911
R01 · FY2017 · HL
Airway Delivery of Fibrinolytic Therapy for ISALI$747,162
R01 · FY2016 · HL · contact PI
Airway Delivery of Fibrinolytic Therapy for ISALI$743,484
R01 · FY2015 · HL · contact PI
Single chain urokinase plasminogen activator (scuPA) for treatment of loculated complicated parapneumonic effusions and empyema$74,071
U01 · FY2015 · HL · contact PI
Airway Delivery of Fibrinolytic Therapy for ISALI$780,701
R01 · FY2014 · HL · contact PI
PAI-1 Targeted Intrapleural Fibronolytic Therapy$424,780
P50 · FY2012 · HL · contact PI
PAI-1 Targeted Intrapleural Fibronolytic Therapy$443,323
P50 · FY2011 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$1,609,098
P01 · FY2009 · HL · contact PI
Control of Fibrin Turnover in Pleural Disease$379,378
P01 · FY2009 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$1,540,013
P01 · FY2008 · HL · contact PI
Control of Fibrin Turnover in Pleural Disease$368,194
P01 · FY2008 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$18,499
P01 · FY2008 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$1,471,629
P01 · FY2007 · HL · contact PI
Control of Fibrin Turnover in Pleural Disease$408,414
P01 · FY2007 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$77,000
P01 · FY2007 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$1,476,651
P01 · FY2006 · HL · contact PI
Control of Fibrin Turnover in Pleural Disease$368,948
P01 · FY2006 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$8,466
P01 · FY2006 · HL · contact PI
Fibrinolytic Pathways in Lung Injury and Repair$1,534,853
P01 · FY2005 · HL
Control of Fibrin Turnover in Pleural Disease$358,622
P01 · FY2005 · HL
Administrative Core$94,637
P01 · FY2005 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$268,124
R01 · FY2004 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$266,140
R01 · FY2003 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$264,214
R01 · FY2002 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$262,344
R01 · FY2001 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$260,528
R01 · FY2000 · HL
CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE$130,059
R01 · FY2000 · HL